3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and comp...

Full description

Saved in:
Bibliographic Details
Main Authors KELLUM, ALEX ANDREW, BLANCHE, SYDNEY TAYLOR, REN, LI, DOERNER BARBOUR, PATRICK MICHAEL, MORENO, DAVID AUSTIN, DAHLKE, JOSHUA RYAN, WITKOS, FAITH ELIZABETH, BLAKE, JAMES FRANCIS, CLARK, WESLEY DEWITT, COWDREY, CONNOR JAMES, KNAPP, ELLEN MARGARET, O'LEARY, JACOB MATTHEW, BOYS, MARK LAURENCE, ALLEN, SHELLEY
Format Patent
LanguageChinese
English
Published 01.02.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.
Bibliography:Application Number: TW202211111624